Navigation Links
Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
Date:6/18/2008

PhenoSense GT(TM) and PhenoSense Integrase(TM) assays used to study

promising new Integrase inhibitor

SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced today that the Company has signed an agreement with Gilead Sciences, Inc. to provide resistance testing and consultative services for Gilead's Elvitegravir Phase III studies. Monogram assays will be used to screen patients for study enrollment and help select drugs to be given in conjunction with Elvitegravir during the study. Both Monogram's Integrase phenotype and genotype assays were used in Elvitegravir preclinical and Phase II studies, and will be used to evaluate Phase III patient outcomes. The Phase III studies are anticipated to begin enrolling patients later this year.

Elvitegravir is the most recent Gilead drug to enter Phase III and is the latest drug in the promising new class of drugs known as "Integrase inhibitors." Integrase is a viral enzyme that helps HIV integrate its genetic material into a healthy cell's DNA, allowing that cell to begin producing genetic material for new viruses. Integrase inhibitors block the action of this enzyme, interrupting the HIV life cycle before it can begin reproducing.

"Momentum in new ways to combat HIV, such as Integrase inhibitors, is vital to dealing with a virus that is becoming increasingly difficult to treat," said Bill Young, Monogram's chief executive officer. "The Elvitegravir development program shows the importance of strong collaborations between diagnostic and drug makers to more quickly get powerful new treatments into the hands of those who need them most."

About Monogram

Monogram is a biotechnology compa
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
6. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Anaptys Biosciences Raises Over $33 Million in Series B Financing
10. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... records to understand the best available treatment for patients, ... and less costly for taxpayers than the existing clinical ... Professor van Staa, carried out while he was a ... who is now based at The University of Manchester,s ... ( HTA ) today (Friday 11 July) looked ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... the risk for stroke, a new study suggests. The ... a stroke or a transient ischemic attack (TIA) by ... or TIA risk by 59 percent. And hostility doubled the ... by a temporary blockage of blood flow to the brain. ...
(Date:7/11/2014)... conducted at Aarhus University has revealed that people who ... only half as likely as their urban counterparts to ... and Crohn,s disease. The study findings have recently been ... , "It is extremely exciting that we can now ... classic inflammatory diseases appear to depend on the environment ...
(Date:7/11/2014)... As reported by Forbes in the article Robert Downey ... (6/30), Indino Downey has reportedly been arrested after being ... with. His father, well-known actor Robert Downey Jr. believes ... may have something to do with his addiction struggles. ... and 1990s for substance abuse before finally getting clean ...
(Date:7/11/2014)... July 11, 2014 Having experienced mental illness ... member of mental hospital staff, Roger Grainger gives readers an ... in his new book, “You Never Get Out.” , According ... the United Kingdom will experience some kind of mental health ... still needs to take a look at the way mental ...
Breaking Medicine News(10 mins):Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2
... for "tennis elbow" but needs to be injected properly ... CMAJ ( Canadian Medical Association Journal ) ... a randomized controlled trial of 48 patients, was performed ... University of Medical Sciences that serves patients from all ...
... HACKENSACK, N.J. (April 26, 2010, 4 p.m. EDT) Myelodysplastic syndromes ... are nearly five times more common in seniors than previously ... John Theurer Cancer Center at Hackensack University Medical Center. ... patients are at much higher risk for heart attack, diabetes ...
... predict which are most likely to be good candidates ... News) -- U.S. researchers have developed a new tool ... potential organ donors, a development that could potentially boost ... damage are often good candidates for organ donation when ...
... diabetes now widespread, CDC survey finds , MONDAY, April ... adults have either high blood pressure, high cholesterol or ... stroke and other cardiovascular problems, a new government survey ... Health and Nutrition Examination Survey (NHANES) 1999-2006 shows that ...
... VA - The American Society of Pediatric Otolaryngology (ASPO) ... 2, during the 2010 Combined Otolaryngology Spring Meetings (COSM) ... Las Vegas, NV. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Readers are ... his interest and research on improving ones state of life. This book helps readers to ... strives to touch all walks of life. , ... Washington, D.C. (Vocus) April 26, 2010 -- Thomas Finn is ...
Cached Medicine News:Health News:Botulinum injection provides relief of tennis elbow 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 3Health News:Test Spots Potential Organ Donors Among Coma Patients 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company ... results of a Phase 2b trial for Empatic(TM) on Wednesday, ... will be followed by a live webcast and conference call ... the call and webcast to discuss the results of this ...
... Pharmaceutical Major, Lupin Ltd. announced today the acquisition of ... mg). Lupin acquired the product from Oscient Pharmaceuticals on ... Court. Antara recorded net sales of US $ 70 ... $ 38.61 million for the product and related assets inclusive ...
Cached Medicine Technology:Lupin Expands Branded Play 2Lupin Expands Branded Play 3
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
... VACUETTE® erythrocyte sedimentation rate analysers, which ... new generation unites the well-established advantages ... range of additional innovations which guarantee ... sedimentation rate. Cost effectiveness is an ...
... ESR analyzer that brings about ... pipettes. Up to 40 test ... or bach, with automated mixing. ... for back-up support or to ...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: